PWG
TGTX icon

Portside Wealth Group’s TG Therapeutics TGTX Stock Holding History

Portside Wealth Group’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$904K Buy
16,458
+2,630
+19% +$108K 0.11% 209
2026
Q1 		$459K Buy
13,828
+1,777
+15% +$53K 0.06% 275
2025
Q4 		$359K Buy
+12,051
New +$394K 0.05% 325

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Portside Wealth Group's TGTX Position: Q2 2026 in Review

Portside Wealth Group increased its TG Therapeutics (TGTX) stake by 19% in Q2 2026, buying an estimated $108K and bringing the position to 16,458 shares worth $904K. The position accounts for 0.11% of the portfolio, ranked #209.

Portside Wealth Group first reported a position in TGTX in Q4 2025 and has held it in 3 quarters since. 428 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Portside Wealth Group held 16,458 shares of TG Therapeutics worth $904K as of Q2 2026.
  • Portside Wealth Group bought 2,630 TG Therapeutics shares in Q2 2026, an estimated $108K.
  • TG Therapeutics made up 0.11% of Portside Wealth Group's portfolio in Q2 2026, its #209 holding.
  • Portside Wealth Group first reported a position in TG Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 428 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Portside Wealth Group's 13F filing for Q2 2026, filed 14 Jul 2026.